Cheryl joined Nura Bio as Senior Vice President, Drug Discovery in May 2021. In this role, she brings over 25 years of biotech and large pharma experience leading research teams across multiple therapeutic areas, including CNS and Immunology, resulting in the advancement of over a dozen New Molecular Entities (NMEs) into the clinic. Cheryl joined Nura Bio from Lundbeck, where she served as Vice President of Chemistry following the acquisition of Abide, where she had been in a similar role. At Lundbeck, Cheryl was responsible for the progression of compounds from discovery to early development in a leadership role spanning the U.S. and Denmark. She also spearheaded an initiative to accelerate compounds to First-in-Human studies within the broader R&D organization. At Abide, Cheryl successfully led Chemistry and Chemistry, Manufacturing and Controls (CMC) functions in delivering five development candidates into IND-enabling and early clinical studies in six years. Prior to joining Abide, she served in medicinal chemistry research roles of increasing scope and responsibility at Schering-Plough Research Institute and Janssen Research & Development. Cheryl obtained her PhD in Synthetic Organic Chemistry from Duke University and completed a post-doctoral fellowship under the direction of Samuel Danishefsky at the Sloan-Kettering Institute, contributing to the total synthesis of Taxol™.